Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Misses Expectations By $0.07 EPS

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07), Zacks reports. The firm had revenue of $164.88 million for the quarter, compared to the consensus estimate of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%.

Ultragenyx Pharmaceutical Trading Down 2.4 %

RARE stock traded down $1.03 during trading on Monday, hitting $42.49. 1,211,521 shares of the stock traded hands, compared to its average volume of 802,763. Ultragenyx Pharmaceutical has a one year low of $37.02 and a one year high of $60.37. The stock has a market cap of $3.92 billion, a price-to-earnings ratio of -6.57 and a beta of 0.60. The company has a 50 day simple moving average of $43.46 and a 200 day simple moving average of $49.59.

Analyst Ratings Changes

RARE has been the subject of several recent analyst reports. Royal Bank of Canada reaffirmed an "outperform" rating and set a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Wedbush reaffirmed a "neutral" rating and set a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. TD Cowen increased their price target on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a "buy" rating in a report on Monday, October 21st. Piper Sandler raised their price objective on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an "overweight" rating in a report on Monday, January 13th. Finally, Wells Fargo & Company raised their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a report on Friday, December 20th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $92.43.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 8,273 shares of the business's stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total value of $413,650.00. Following the completion of the transaction, the chief executive officer now directly owns 2,195,712 shares of the company's stock, valued at approximately $109,785,600. The trade was a 0.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 5.80% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.